Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences does not face any business risks ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00. Patrick Trucchio’s rating is based on Sangamo ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

Alexander Macrae; President, Chief Executive Officer, Director; Sangamo Therapeutics Inc Nathalie Dubois- Stringfellow; Senior Vice President, Chief Development Officer; Sangamo Therapeutics Inc ...

Sangamo Therapeutics Inc (NASDAQ:SGMO) has transformed from a Phase 1/2 company to a pre-BLA company due to significant ...

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.

RICHMOND, Calif. (AP) — RICHMOND, Calif. (AP) — Sangamo Therapeutics Inc. (SGMO) on Tuesday reported third-quarter earnings of $10.7 million. On a per-share basis, the Richmond, California-based ...

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $5.00 to $10.00. HC ...

On Tuesday, Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $2.16 which represents a slight increase of $0.42 or 24.14% from the prior close of $1.74. The stock opened at ...